Keppra (levetiracetam) is not a controlled substance. It does not appear on the DEA’s list of scheduled drugs under the Controlled Substances Act, which means it carries no special prescribing restrictions, no DEA monitoring, and no legal limits on refills. Your pharmacy can process it like any standard prescription medication.
Why Keppra Is Not Scheduled
The DEA places drugs into controlled substance schedules based on their potential for abuse, physical dependence, and whether they produce a “high.” Keppra works through a mechanism that doesn’t lend itself to any of these concerns. It binds to a protein called SV2A on the surface of synaptic vesicles, which are tiny packets that neurons use to release chemical signals. By modulating this protein, Keppra reduces excessive electrical activity in the brain without stimulating the reward pathways that drive addiction.
This mechanism is distinct from nearly every other seizure medication on the market. It doesn’t boost calming brain chemicals the way benzodiazepines or barbiturates do, and it doesn’t produce the sedative euphoria that makes those drugs attractive for misuse. The FDA’s clinical review of Keppra did not identify withdrawal phenomena or abuse potential as areas of concern.
Seizure Medications That Are Controlled
Keppra’s non-controlled status is somewhat unusual among epilepsy drugs. Several commonly prescribed anticonvulsants are federally scheduled:
- Phenobarbital, a barbiturate with well-established abuse potential
- Clonazepam and clobazam, both benzodiazepines
- Pregabalin (Lyrica), which can produce feelings of relaxation and euphoria at higher doses
- Brivaracetam (Briviact), a close chemical relative of Keppra that nonetheless carries a Schedule V designation
- Lacosamide (Vimpat)
- Perampanel (Fycompa)
- Cenobamate (Xcopri)
- Fenfluramine (Fintepla)
Gabapentin is an interesting case: it is not federally scheduled, but several states have reclassified it as a controlled substance due to rising misuse. Keppra has not faced similar reclassification anywhere.
The fact that brivaracetam is controlled while Keppra is not sometimes surprises people, since both drugs target the same SV2A protein. The difference comes down to brivaracetam’s higher binding affinity and its demonstrated potential for psychoactive effects at certain doses, which led the DEA to schedule it.
What This Means for Prescriptions and Refills
Because Keppra is not controlled, your doctor can prescribe refills in advance, and you can fill them at any pharmacy without the restrictions that apply to scheduled drugs. There is no requirement for a new written prescription each month, no limit on the number of refills per prescription, and no mandatory waiting period between fills. If you use mail-order pharmacy services, Keppra can typically be shipped in 90-day supplies without additional paperwork.
For travel, the TSA recommends labeling prescription medications but does not require it for non-controlled drugs. You can carry Keppra in your carry-on or checked luggage without any special documentation. International travel rules vary by country, but non-controlled medications generally face far less scrutiny at customs than scheduled ones. Keeping the pharmacy label on the bottle is still a good idea if you’re crossing borders.
Side Effects That May Raise Concerns
Even though Keppra lacks abuse potential, it does cause behavioral side effects that sometimes prompt questions about its classification. The FDA lists unusual irritability, aggression, confusion, loss of coordination, and extreme drowsiness as common side effects. Some people experience personality changes significant enough that the phenomenon has earned the informal nickname “Keppra rage” among patients and neurologists.
These mood and behavior changes are not signs of dependence or withdrawal. They result from levetiracetam’s effects on brain signaling and typically emerge within the first few weeks of treatment. In 2008, the FDA issued a broader communication about suicidal behavior and ideation across all antiepileptic drugs, including Keppra. These psychiatric effects are a known pharmacological side effect, not evidence of a drug with abuse potential.
Stopping Keppra abruptly is still not recommended, but for a different reason than with controlled substances. Suddenly discontinuing any seizure medication can trigger rebound seizures, which is a neurological risk rather than a sign of physical addiction. Doctors typically taper the dose gradually when transitioning off the drug.